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Abstract: Intracranial major artery stenosis/occlusion (ICASO) is the major cause of ischemic
stroke. Recent studies have suggested that variants of RNF213, a susceptibility gene for moyamoya
disease (MMD), are also related to non-MMD ICASO. Regarding the predominant involvement
of steno-occlusion on anterior circulation in MMD, we hypothesized that the ICASO distribution
pattern (anterior/posterior) in non-MMD may differ according to RNF213 variants. This study
analyzed 1024 consecutive Korean subjects without MMD who underwent computed tomography
angiography (CTA) or magnetic resonance angiography (MRA). We evaluated four single nucleotide
polymorphisms (SNPs) in the exon region of RNF213: 4448G > A (rs148731719), 4810G > A
(rs112735431), 4863G > A (rs760732823), and 4950G > A (rs371441113). Associations between RNF213
variants and anterior/posterior ICASO were examined using multivariate logistic regression analysis.
Anterior ICASO was present in 23.0% of study subjects, and posterior ICASO was present in 8.2%.
The GA genotype of RNF213 4810G > A (adjusted odds ratio (AOR) [95% confidence interval (CI)],
2.39 [1.14–4.87] compared to GG; p = 0.018) and GA genotype of RNF213 4950G > A (AOR [95% CI],
1.71 [1.11–2.63] compared to GG; p = 0.015) were more frequent in subjects with anterior ICASO.
The genotype frequency of RNF213 4863G > A differed significantly according to the presence of
posterior ICASO. Further investigations of the functional and biological roles of RNF213 will improve
our understanding of the pathomechanisms of ICASO and cerebrovascular disease.
Keywords: intracranial major artery stenosis/occlusion; RNF-213; moyamoya disease; single
nucleotide polymorphism
1. Introduction
Intracranial major artery stenosis/occlusion (ICASO) is the major cause of ischemic stroke [1,2].
ICASO can result from atherosclerosis, thromboembolism, or non-atherosclerotic vascular disease,
such as dissection, vasculitis, or moyamoya disease (MMD) [3]. Really interesting new gene (RING)
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finger protein 213 (RNF213) is encoded by the RNF213 gene (DDBJ/EMBL/GenBank accession number
AB537889) on chromosome 17q25, which has received considerable attention as a susceptibility gene
for MMD and ICASO in Asians [4–6]. The functional role of RNF213 on cerebral vasculature has not
been established, but experimental studies have suggested that it affects cerebral blood perfusion,
angiogenesis, and oxygen consumption [7–10].
ICASO can be present in anterior and posterior cerebral circulation. It has been known that
anterior and posterior ICASO differs in clinical characteristics, risk factors, histopathology, and genetic
susceptibility [11–13]. RNF213 is recognized as the major susceptibility gene for MMD, which is typically
characterized by progressive steno-occlusive changes in the terminal part of the internal carotid arteries
and/or their branches (anterior circulation) [14,15]. Regarding the potential genetic contributions to
ICASO, we hypothesized that the distribution of anterior/posterior ICASO in non-MMD may also
differ according to genetic variants of RNF213. To test our hypothesis, we assessed the association
between four single nucleotide polymorphisms (SNPs) in the exon region of RNF213 (4448G > A,
4810G > A, 4863G > A, and 4950G > A) and the distribution pattern of ICASO in non-MMD Koreans.
2. Results
2.1. Characteristics
This study included 1024 non-MMD subjects (636 ischemic stroke and 388 non-stroke subjects)
who underwent genotyping of RNF213 variants and angiographic evaluation. Their mean age was
63.6 ± 11.4 years, and 47.0% were male. Baseline characteristics of the study subjects are shown in
Table 1. ICASO was present in 27.6%. Compared with subjects without ICASO, those with ICASO were
more likely to be older and have hypertension, diabetes mellitus (DM), and ischemic stroke. Regarding
the distribution of ICASO, 23.0% of subjects had anterior ICASO, and 8.2% had posterior ICASO.
Table 1. Clinical characteristics of study subjects.
Variable Totaln = 1024
ICASO (-)
n = 788
ICASO (+)
n = 236 p-Value
1
Sex, male 481 (47.0) 353 (47.6) 128 (45.2) 0.535
Age, years 63.6 ± 11.4 62.5 ± 11.5 66.2 ± 10.4 <0.001
Medical history
Hypertension 542 (52.9) 373 (50.3) 169 (59.7) 0.009
Diabetes mellitus 214 (20.9) 138 (18.6) 76 (26.9) 0.005
Hypercholesterolemia 280 (27.3) 195 (26.3) 85 (30.0) 0.265
Atrial fibrillation 59 (5.8) 38 (5.1) 21 (7.4) 0.208
Ischemic stroke 636 (62.1) 386 (52.1) 250 (88.3) <0.001
ICASO in anterior cerebral circulation † 236 (23.0) - 236 (83.4) -
ICASO in posterior cerebral circulation ‡ 84 (8.2) - 84 (29.7) -
Note: Data are expressed as numbers (%) or mean ± standard deviation. ICASO, intracranial major artery
stenosis/occlusion. 1 Comparison between ICASO (-) and ICASO (+). † Intracranial internal carotid artery, anterior
cerebral artery, or middle cerebral artery. ‡ Intracranial vertebral artery, basilar artery, or posterior cerebral artery.
2.2. RNF213 Genotypes
Table 2 shows the genotype frequencies of the RNF213 variants. For RNF213 4448G > A,
the frequency of minor allele (A) was 7.7%. The minor allele (A) frequencies of 4810G > A, 4863G > A,
and 4950G > A were 2.0%, 11.7%, and 7.0%, respectively. Carrier frequencies of at least one A allele
(minor allele) for the four SNPs were 14.9%, 4.0%, 22.2%, and 13.6%. The distribution of RNF213
polymorphisms satisfied the Hardy–Weinberg equilibrium.
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Table 2. Genotypes of RNF213 variants.
Genotype
RNF213 Single Nucleotide Polymorphism (RefSNP Number)
4448G > A
(rs148731719)
4810G > A
(rs112735431)
4863G > A
(rs760732823)
4950G > A
(rs371441113)
GG 826 (85.1) 983 (96.0) 755 (77.8) 839 (86.4)
GA 140 (14.4) 41 (4.0) 204 (21.0) 128 (13.2)
AA 5 (0.5) 0 (0) 12 (1.2) 4 (0.4)
p-value for test of HWE >0.999 >0.999 0.7582 >0.999
Note: Data are expressed as numbers (%). HWE, Hardy–Weinberg equilibrium; RNF213, RING finger protein
213 gene.
2.3. Relationship between RNF213 Genotypes and ICASO
Table 3 shows the genotype distribution of RNF213 variants according to the presence of ICASO.
Table 3. Genotype distribution of RNF213 variants according to the presence of ICASO.
RNF213
Polymorphism
(RefSNP Number)
Genotype Frequency (GG/GA/AA)
ICASO (-) ICASO (+) AnteriorICASO (-)
Anterior
ICASO (+)
Posterior
ICASO (-)
Posterior
ICASO (+)
4448G > A
(rs148731719) 596/100/3 230/40/2 638/103/4 188/37/1 753/132/4 73/8/1
4810G > A
(rs112735431) 716/25/0 267/16/1 762/26/0 221/15/1 703/37/0 80/4/1
4863G > A
(rs760732823) 535/158/6 220/46/6 576/161/8 179/43/4 684/198/7 71/6/5
4950G > A
(rs371441113) 613/83/3 226/45/1 655/86/4 184/42/0 767/119/3 72/9/1
Note: Data are expressed as numbers. ICASO, intracranial major artery stenosis/occlusion.
We investigated the relationships between distributions of the four RNF213 variants and the presence
of ICASO using multivariate logistic regression analysis (Table 4). Patients with ICASO were more likely
to have the RNF213 4810 (rs112735431) GA genotype than the GG genotype, but the association was
not statistically significant (adjusted odds ratio (AOR) [95% confidence intervals (CI)], 2.05 [0.98–4.21];
p = 0.053). None of the other RNF213 variants were associated with the presence of ICASO.
Table 4. Risk of ICASO according to genotype of RNF213 variants.
RNF213
Polymorphism
Genotype
ICASO Anterior ICASO Posterior ICASO
AOR
(95% CI) p-Value
AOR
(95% CI) p-Value
AOR
(95% CI) p-Value
4448G > A
(rs148731719)
GG 1.00 (ref) - 1.00 (ref) - 1.00 (ref) -
GA 1.21(0.79–1.86) 0.388
1.43
(0.92–2.21) 0.109
0.74
(0.32–1.53) 0.454
AA 1.51(0.23–9.98) 0.671
0.71
(0.04–5.27) 0.769
2.32
(0.11–17.92) 0.473
Dominant (GG
vs. GA + AA)
1.22
(0.79–1.86) 0.356
1.40
(0.90–2.14) 0.131
0.80
(0.36–1.60) 0.562
Recessive (GG
+ GA vs. AA)
1.46
(0.18–9.83) 0.693
0.67
(0.03–4.97) 0.732
2.41
(0.12–18.64) 0.451
4810G > A
(rs112735431) 2
GG 1.00 (ref) - 1.00 (ref) - 1.00 (ref) -
GA 2.05(0.98–4.21) 0.053
2.39
(1.14–4.87) 0.018
1.23
(0.35–3.35) 0.708
AA NA NA NA
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Table 4. Cont.
RNF213
Polymorphism
Genotype
ICASO Anterior ICASO Posterior ICASO
AOR
(95% CI) p-Value
AOR
(95% CI) p-Value
AOR
(95% CI) p-Value
4863G > A
(rs760732823)
GG 1.00 (ref) - 1.00 (ref) - 1.00 (ref) -
GA 0.69(0.47–1.02) 0.067
0.86
(0.57–1.28) 0.467
0.29
(0.11–0.64) 1 0.005
AA 2.96(0.79–11.24) 0.104
1.66
(0.44–6.27) 0.453
8.55
(2.17–32.51) 1 0.002
Dominant (GG
vs. GA + AA)
0.76
(0.52–1.10) 0.157
0.90
(0.61–1.32) 0.588
0.52
(0.25–0.98) 1 0.043
Recessive (GG
+ GA vs. AA)
3.19
(0.86–12.12) 0.081
1.72
(0.42–6.27) 0.425
10.32
(2.62–39.22) 1 <0.001
4950G > A
(rs371441113)
GG 1.00 (ref) - 1.00 (ref) - 1.00 (ref) -
GA 1.43(0.93–2.19) 0.100
1.71
(1.11–2.63) 1 0.015
0.82
(0.36–1.63) 0.589
AA 0.49(0.02–3.98) 0.542 NA
2.28
(0.11–19.34) 0.489
Dominant (GG
vs. GA + AA)
1.38
(0.90–2.10) 0.133
1.59
(1.03–2.44) 1 0.033
0.87
(0.40–1.70) 0.700
Recessive (GG
+ GA vs. AA)
0.46
(0.02–3.74) 0.510 NA
2.35
(0.11–19.90) 0.473
Note: Data are adjusted odds ratios (AOR) and 95% confidence intervals (CI) derived from multivariate logistic
regression models adjusting for sex, age, and presence of hypertension, diabetes mellitus, hypercholesterolemia,
atrial fibrillation, or ischemic stroke. ICASO, intracranial major artery stenosis/occlusion; NA, not applicable
(no cases in the arm). 1 p-value <0.05. 2 For RNF213 4810G > A, analysis for dominant and recessive models was
omitted due to there being no subject with AA genotype.
2.4. Relationship between RNF213 Genotypes and Anterior/Posterior ICASO
When we evaluated the relationship between RNF213 variants and the distribution of ICASO
(anterior/posterior) using the multivariate logistic regressions (Table 4), anterior ICASO was significantly
associated with the RNF213 4810 (rs112735431) GA genotype (AOR [95% CI], 2.39 [1.14–4.87]; p = 0.018)
compared with the GG genotype. Anterior ICASO was also significantly more likely with the RNF213
4950 (rs371441113) GA genotype (AOR [95% CI], 1.71 [1.11–2.63]; p = 0.015) compared with the
GG genotype. In the analysis regarding the posterior ICASO, the presence of posterior ICASO was
significantly associated with the RNF213 4863 (rs760732823) genotype. Compared with the RNF213
4863 GG genotype, the GA genotype was associated with lower likelihood of posterior ICASO (AOR
[95% CI], 0.29 [0.11–0.64]; p = 0.005), but the AA genotype was associated with higher odds of posterior
ICASO (AOR [95% CI], 8.55 [2.17–32.51]; p = 0.002).
2.5. Haplotype Analysis
We evaluated the linkage disequilibrium of the RNF213 variants (4448G > A (rs148731719)/4810G
> A (rs112735431)/4863G > A (rs760732823)/4950G > A (rs371441113)) using the Haploview program
(Figure 1). Among the four SNPs, there was a strong linkage disequilibrium (0.73 of D′ statistic and
0.480 of r2) between loci 4448G > A (rs148731719) and 4950G > A (rs371441113). Other combinations of
RNF213 SNPs did not exhibit strong linkage disequilibrium.
We performed haplotype analyses of the four SNPs for the presence of ICASO, anterior ICASO,
and posterior ICASO (Table 5). In the haplotype analyses, GAGG (4448G/4810A/4863G/4950G) was
associated with a significantly increased risk of ICASO and anterior ICASO. Other combinations did
not show significant association with ICASO distribution.
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Table 5. Haplotype analysis of RNF213 variants for the presence of ICASO.
Haplotype
Frequency
ICASO A rior ICASO Posterior ICASO
RNF213
4448/4810/4863/4950
AOR
(95% CI) p-Value
AOR
(95% CI) p-Value
AOR
(95% CI) p-Value
GGGG 0.784 1.00 (ref) - 1.00 (ref) - 1.00 (ref) -
AGGA 0.047 1.26(0.76–2.10) 0.371
1.37
(0.81–2.32) 0.246
1.01
(0.46–2.24) 0.978
AGGG 0.024 1.02(0.45–2.30) 0.964
1.41
(0.64–3.13) 0.398
0.31
(0.04–2.35) 0.258
GAGG 0.014 2.86(1.15–7.11) 0.023
4.01
(1.63–9.87) 0.002
1.28
(0.33–4.97) 0.725
GA 0.104 0.87(0.59–1.28) 0.472
0.95
(0.64–1.43) 0.811
0.88
(0.49–1.59) 0.680
Rare * 0.016 1.43(0.48–4.28) 0.518
2.06
(0.69–6.12) 0.193
0.62
(0.08–4.88) 0.646
Note: Adjusted odds ratio (AOR) and 95% confidence interval (CI) were computed for each haplotype and
compared to the most common haplotype (GGGG). Adjustments were made for sex, age, and the presence of
hypertension, diabetes mellitus, hyperlipidemia, atrial fibrillation, or ischemic stroke. ICASO, intracranial major
artery stenosis/occlusion. * Other rare combinations besides the above haplotypes.
3. Discussion
In the current study, we evaluated the distribution of four polymorphisms in the exon sequence of
RNF213, the MMD susceptibility gene, and the relationship between these polymorphisms and ICASO
in non-MMD Koreans. We found that RNF213 4810G > A (rs112735431) and 4950G > A (rs371441113)
were significantly associated with the presence of anterior ICASO, whereas RNF213 4863G > A
(rs760732823) was associated with posterior ICASO. If further studies validate the relationship between
the RNF213 variants and anterior/posterior ICASO, detection of RNF213 variants could be applicable
to a screening method for ICASO or prediction of disease prognosis. Discovery of a pathogenic role of
RNF213 gene in ICASO may provide a novel therapeutic target in ICASO with high risk for stroke.
The RNF213 gene encodes a RING finger protein that possesses both ubiquitin ligase activity
and ATPases associated with diverse cellular activities’ (AAA+) ATPase activity [16]. Although
RNF213 variants have been associated with various vascular disorders, the mechanisms through
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which they contribute to these disorders are unknown [17]. Experimental reports have suggested
multiple pathogenic mechanisms involving endothelial function, smooth muscle cell proliferation,
inflammatory signaling pathways, hemostasis, angiogenesis, vascular remodeling, and response to
hypoxia [7,9,10,18–22]. However, an RNF213-deficient mouse model did not exhibit any vascular
abnormality [23]. Currently, the exact biochemical and pathologic roles of RNF213 in vascular disorders
remain controversial.
Beyond conflicting reports regarding the functional role of RNF213, epidemiologic data have
shown significant associations between RNF213 variants and intracranial vascular disorders including
MMD, ICASO, cerebral artery dissection, and intracranial aneurysm [4,24–26]. At least 24 genetic
changes in RNF213 have been associated with MMD [21]. The RNF213 4810G > A (rs112735431)
is considered a major genetic risk factor for MMD; the carrier rate of this SNP in East Asians with
MMD is >70% [18,27,28]. Although the RNF213 4810G > A variant has never been detected in
Caucasians, there are rare missense RNF213 variants, which have been associated with MMD in
Caucasians, especially those with childhood-onset or familial disease [29,30]. Beyond the association
with MMD, a number of studies have reported frequent RNF213 variants in patients with non-MMD
ICASO [2,31,32]. In a meta-analysis of 11 studies including 1778 ICASO patients and 3140 controls
in East Asians, RNF213 4810G > A was significantly associated with an increased risk of ICASO [17].
High-resolution magnetic resonance angiography (MRA) showed that ICASO with RNF213 4810G > A
was associated with a negative remodeling pattern, which is a hallmark of MMD, in contrast to the
positive remodeling pattern of classical atherosclerotic ICASO [33]. In addition to the relationship with
the presence of intracranial cerebrovascular disease, RNF213 variant genotypes may also be associated
with the disease progression and long-term outcome. Among patients with MMD, the homozygous
variant of RNF213 4810G > A was associated with an increased likelihood of onset at a younger age,
cerebral infarction at diagnosis, and cognitive impairment during long-term follow-up [34]. In a study
of 59 relatives of patients with MMD, RNF213 4810G > A heterozygous carriers had a higher risk of
developing ICASO during angiographic follow-up [35]. The presence of RNF213 4810G > A variant was
at increased risk for ischemic stroke, which was largely attributable to large-artery atherosclerosis [36].
Recent reports have also described associations between RNF213 variants and extracranial systemic
vasculopathy involving coronary, renal, and pulmonary arteries [37–39].
Because of the predominant involvement of the anterior cerebral circulation in MMD, we
hypothesized that the distribution pattern of ICASO may differ according to RNF213 variants. In our
results, we found that RNF213 4810G > A (rs112735431) and 4950G > A (rs371441113) increased the
likelihood of anterior ICASO. Both of these variants have been reported to be significantly associated
with MMD in Korean and Chinese populations [18,21,40,41]. Similarly, there was a study of 221 Japanese
patients, which found that RNF213 4810G > A was significantly associated with anterior ICASO but
not posterior ICAS [42]. In the case-control study with a total of 46,958 Japanese people, RNF213 4810G
> A variant carriers more frequently had intracranial anterior circulation stenosis than non-carriers
(60.0% versus 27.3%, p = 0.004) [36]. Another study of 70 early-onset stroke patients with ICASO in
Japan found that 17 RNF213 4810G > A carriers had anterior ICASO, whereas only 1 carrier of this
variant had posterior ICASO as well, and the RNF213 4810G > A variant was more common in patients
with MCA or ACA stenosis (17/44) than in patients with posterior ICASO (1/11) [43]. However, there
have also been negative reports indicating that the distribution of anterior and posterior ICASO did not
differ between RNF213 variant carriers and non-carriers [2,32]. The inconsistent results between studies
may be attributed to differences in study populations; the two negative reports included only ICASO
(+) subjects and compared the distribution of anterior and posterior ICASO according to RNF213
variants. Because of our limited understanding of the pathogenetic role of RNF213 and insufficient
clinical data, it is difficult to make conclusions regarding the relationships between RNF213 variants
and distribution patterns of ICASO. However, predominant involvement of the anterior cerebral
circulation in carriers with RNF213 variants of 4810G > A and 4950G > A suggests an inter-relationship
between ICASO and MMD and the possibility of a shared genetic pathomechanism.
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In the current study, the presence of posterior ICASO differed significantly according to the
genotype distribution of RNF213 4863G > A (rs760732823). As underlying risk factors and genetic
predisposition differ between anterior and posterior ICASO, RNF213 variants may have divergent
effects on the anterior and posterior cerebral circulations [13]. To our knowledge, no prior report
has shown a significant relationship between RNF213 variants and posterior ICASO. Interestingly,
compared with the GG wild type of 4863G > A (rs760732823), the GA genotype was associated with a
lower risk of posterior ICASO, but the AA genotype was associated with a higher risk. Compared
with RNF213 4810 (rs112735431) and 4950 (rs371441113), which are both susceptibility genes for MMD,
little is known about RNF213 4863G > A (rs760732823). We previously evaluated the distribution of
RNF213 4863G > A between Korean MMD patients and controls; there was no significant difference
according to RNF213 4863G > A [21]. More research is required to verify whether the relationship
between RNF213 4863G > A and posterior ICASO is duplicated in other study populations.
We acknowledge potential limitations of this study. Although many studies have reported
associations between RNF213 variants and cerebrovascular disorders, the underlying pathogenic
process has not been established. Without understanding the pathogenetic mechanisms, our data from
case-control design could not access the causal relationship between RNF213 variants and ICASO.
Furthermore, ICASO and MMD, both RNF213-related disorders, are progressive cerebrovascular
diseases [35,44]. Because our study lacked follow-up data, we did not provide information about the
progression of ICASO or the prognostic value of RNF213 variants. ICASO is a heterogeneous disease,
influenced by various environmental and genetic factors [2,45]. Although atherosclerotic stenosis of
a major intracranial artery is the most common type of ICASO, different etiologies and risk factors
can influence the development of ICASO [4,31]. We adjusted for multiple conventional vascular risk
factors, but the possibility of unknown potential confounding factors remains. Although we excluded
MMD patients based on angiographic findings, it is possible that patients with early changes or atypical
patterns of MMD might have been included, which may have contributed to the association between
ICASO and RNF213 variants [17,31,33]. In addition, the study was performed at a single hospital,
and a large portion of the study participants had ischemic stroke. Thus, the distribution of RNF213
variants in our subjects may have differed from that in the general population of Koreans. Further
analysis according to the degree of ICASO was lacking in the current study. Use of statins, antiplatelets,
and anti-hypertensive agents may influence the development and progression of ICASO. Unfortunately,
due to the limitations of the retrospective design, we could not collect the data for medications. As the
pathogenesis of MMD is known to be ethnically diverse, the effect of RNF213 variants on ICASO
may have varied in other populations [26]. Moreover, the low prevalence of RNF213 variants and the
small sample size of this study may have limited the statistical power to detect differences between
subgroups and gene–environmental interactions. We assessed four SNPs in the current study, but there
are other potential susceptibility variants in RNF213. To overcome the potential limitations and to
improve our understanding of the influence of RNF213 on ICASO, a wide range of research is required
to explore the genetic pathogenesis and epidemiology of this common cerebrovascular disorder.
4. Methods
4.1. Study Subjects
Study subjects were consecutively recruited from the Department of Neurology at CHA Bundang
Medical Center, CHA University (an 800-bed teaching hospital in Gyeonggi-do, South Korea), between
2001 and 2010 (Figure 2). Subjects were selected from those who underwent blood sampling for
genotyping and cerebral angiographic evaluation by MRA or computed tomography angiography
(CTA). Patients with proximal carotid artery occlusion were excluded because the proximal carotid
occlusion often does not allow the evaluation of intracranial arteries. Individuals who satisfied the
criteria for definite MMD were excluded from the study [43,46]. The medical records were reviewed
to identify the presence of hypertension, DM, hyperlipidemia, atrial fibrillation, or ischemic stroke.
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Hypertension was defined as use of antihypertensive medication or a resting systolic blood pressure
≥140 mmHg or resting diastolic blood pressure ≥90 mmHg on repeated measurements. DM was
defined as use of antidiabetic medications or a fasting plasma glucose ≥7.0 mmol/L or glycosylated
hemoglobin ≥6.5%. Hypercholesterolemia was defined as use of lipid-lowering agents or a low-density
lipoprotein cholesterol ≥4.1 mmol/L or total cholesterol ≥6.2 mmol/L. Ischemic stroke was defined as
acute neurological dysfunction of vascular origin, confirmed by brain magnetic resonance imaging or
computed tomography. All participants provided written informed consent. The study was approved
by the Institutional Review Board of CHA Bundang Medical Center (BD2012-136D).
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4.2. Distribution of ICASO
Angiographic data (MRA or CTA) of the intracranial cerebral arteries were evaluated by two
neurologists (J.K., M.H.W.). ICASO was defined as occlusion or ≥50% stenosis in the intracranial
portion of internal carotid artery (ICA), middle cerebral artery (MCA), anterior cerebral artery (ACA),
posterior cerebral artery (PCA), vertebral artery (VA), or basilar artery (BA). The degree of stenosis
in each intracranial cerebral artery was measured using the Warfarin vs. Aspirin for Symptomatic
Intracranial Disease method [47]. According to the intracranial angiographic findings, the presence of
“anterior ICASO” (involving the ICA, ACA, or MCA) and “posterior ICASO” (involving the PCA, VA,
or BA) was recorded.
4.3. Genotyping of RNF213 Variants
In our prior study, we identified four SNPs in the exon region of RNF213: 4448G > A (rs148731719),
4810G > A (rs112735431), 4863G > A (rs760732823), and 4950G > A (rs371441113) based on prior reports
in Asians and a literature review [21]. Information regarding the SNPs was obtained from the HapMap
database (http://hapmap.ncbi.nlm.nih.gov/). For genotyping of these SNPs, DNA was extracted from
peripheral blood samples using the G-DEX blood extraction kit (iNtRON Biotechnology, Inc., Seongnam,
Korea) according to the manufacturer’s instructions. RNF213 variants were detected by polymerase
chain reaction–restriction fragment length polymorphism (PCR–RFLP) analysis. RNF213 4810G >
A (rs112735431) was evaluated in all study subjects (n = 1024), whereas 4448G > A (rs148731719),
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4863G > A (rs760732823), and 4950G > A (rs371441113) were assessed in 971 subjects. For each SNP,
we randomly repeated approximately 10% of the PCR assays and evaluated concordance with DNA
sequencing using an automatic sequencer (ABI3730 × 1 DNA analyzer; Applied Biosystems, Foster City,
CA, USA). Concordance of these quality control samples was 100%. Details regarding the genotyping
methodology and the RNF213 SNP primer sequences were previously reported [21].
4.4. Statistical Analysis
The characteristics were expressed as mean ± standard deviation for continuous variables (age)
and number (%) for categorical variables. Comparison of characteristics between groups were
performed with independent t-test (continuous variables) or chi-squared test (categorical variables).
RNF213 SNP genotype frequencies were evaluated using the Hardy–Weinberg equilibrium test, which
satisfied the Hardy–Weinberg equilibrium. To assess the relationships between RNF213 variants
and the presence of anterior/posterior ICASO, we calculated AOR and 95% CI using multivariate
logistic regression analysis with the presence of anterior/posterior ICASO as the dependent variable.
Regression models were adjusted for sex, age, and the presence of hypertension, DM, hyperlipidemia,
atrial fibrillation, and ischemic stroke. The statistical analysis was performed with R software
version 3.5.1 (The R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org/).
Linkage disequilibrium maps of RNF213 variants were generated using Haploview version 4.2
(https://www.broadinstitute.org/haploview/haploview) [48]. Two-sided p-value <0.05 was considered
statistically significant.
5. Conclusions
RNF213 variants (4810G > A and 4950G > A) were significantly associated with anterior
ICASO. Conversely, the RNF213 4863G > A variant was significantly associated with posterior
ICASO. Our findings suggest a pathogenetic role of RNF213 in ICASO. There is a clear need for
further investigations elucidating the functional role of RNF213 to better understand the underlying
pathogenesis for cerebrovascular disease.
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